Role of in -positive non-small cell lung cancer.

Anaplastic lymphoma kinase inhibitors have been shown to be effective in treating patients with -positive non-small cell lung cancer (NSCLC), and crizotinib, ceritinib and alectinib have been approved as clinical first-line therapeutic agents. The availability of these inhibitors has also largely changed the treatment strategy for advanced -positive NSCLC. However, patients still inevitably develop resistance to inhibitors, leading to tumor recurrence or metastasis. The most critical issues that need to be addressed in the current treatment of -positive NSCLC include the high cost of targeted inhibitors and the potential for increased toxicity and resistance to combination therapy. Recently, it has been suggested that the serine/threonine kinase 11 () mutation may serve as one of the biomarkers for immunotherapy in NSCLC. Therefore, the main purpose of this review was to summarize the role of in -positive NSCLC. The present review also summarizes the treatment and drug resistance studies in -positive NSCLC and the current status of research in NSCLC.